Archive for June 1, 2012

Licensure of 13-Valent Pneumococcal Conjugate Vaccine for Adults Aged 50 Years and Older

MMWR Weekly   June 1, 2012  V.61 N.21 P.394-395

In 2010, 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals, Inc., a subsidiary of Pfizer, Inc.]) was licensed by the Food and Drug Administration (FDA) and recommended by the Advisory Committee on Immunization Practices (ACIP) for children aged 6 weeks through 71 months for the prevention of invasive pneumococcal disease (IPD) caused by the 13 pneumococcal serotypes included in the vaccine. PCV13 currently is recommended as a 4-dose series for children starting at age 2 months. On December 30, 2011, FDA approved PCV13 for prevention of pneumonia and invasive disease caused by PCV13 serotypes among adults aged 50 years and older. This report summarizes data on the immunogenicity and safety of PCV13 in adults and outlines key additional evidence requested by ACIP to formulate recommendations for its use.

FULL TEXT

http://www.cdc.gov/mmwr/preview/mmwrhtml/mm6121a3.htm?s_cid=mm6121a3_e

PDF (394-395)

http://www.cdc.gov/mmwr/pdf/wk/mm6121.pdf

June 1, 2012 at 3:01 pm

Coinfecciones por HBV y HCV en pacientes HIV positivos en la “era HAART”: nuevos desafíos

Medicina (B. Aires)  Ene/Feb 2007  V.67 N.1

Natalia L. Laufer1, 2, Jorge F. Quarleri2, María B. Bouzas3, Héctor M. Pérez1, Horacio Salomón2, Pedro E. Cahn1

1 Servicio de Infectología, Hospital Juan A. Fernández;

2Centro Nacional de Referencia para el SIDA, Departamento de Microbiología, Universidad de Buenos Aires;

3Unidad de Virología, Hospital Francisco J. Muñiz, Buenos Aires

Dirección postal: Dra. Natalia Laufer, Centro Nacional de Referencia para el SIDA, Paraguay 2155 Piso 11, 1121 Buenos Aires Fax: (54-11) 4508-3705  e-mail: natalialaufer@yahoo.com.ar

Resumen

Las coinfecciones con virus de la hepatitis C (HCV) y/o virus de la hepatitis B (HBV) en pacientes infectados por el virus de la inmunodeficiencia humana (HIV) son un hallazgo frecuente en virtud de las similares vías de transmisión que estos agentes presentan (sexual, parenteral y vertical). Desde el advenimiento del tratamiento antirretroviral de alta eficiencia (TARV) se evidenció una marcada disminución en la morbi-mortalidad de los pacientes; sin embargo, ante la prolongación de su sobrevida, las complicaciones crónicas debidas a las coinfecciones con estos virus hepatotropos han cobrado importancia, convirtiéndose la enfermedad hepática en una de las primeras causas de morbi-mortalidad de los pacientes HIV positivos en los países desarrollados. Se disponen en la actualidad de nuevas terapias y métodos de diagnóstico y seguimiento para HBV y HCV, lo cual permite un mejor control de ambas coinfecciones.

PDF

http://www.scielo.org.ar/pdf/medba/v67n1/v67n1a15.pdf

 

June 1, 2012 at 2:59 pm

Hepatitis B and HIV coinfection.

Hepatology. 2009 May V.49  5 Suppl  S138-45.

Thio CL.

Johns Hopkins University, Division of Infectious Diseases, Baltimore, MD 21205, USA. cthio@jhmi.edu

Abstract

Coinfection with human immunodeficiency virus-1 (HIV) and hepatitis B virus (HBV) is common; worldwide, an estimated 10% of HIV-infected persons have chronic hepatitis B. Because the incidence of traditional acquired immunodeficiency syndrome-related opportunistic infections has decreased with successful anti-HIV therapy, liver disease has emerged as a leading cause of morbidity and mortality in HIV-infected individuals. HIV infection negatively impacts all phases of the natural history of hepatitis B leading to increased rates of persistent infection, higher HBV DNA levels, lower rates of hepatitis B e antigen loss, increased cirrhosis and liver-related mortality, and increased risk of hepatocellular carcinoma at lower CD4+ T cell counts. The management of hepatitis B in HIV infection is complicated by the dual activity of several nucleoside analogs, the more rapid development of lamivudine-resistant HBV in patients who are HIV-positive, and the paucity of studies in this population. Until further research emerges on the optimal treatment for this population, data from HBV monoinfected persons will need to be extrapolated to the HIV-HBV coinfected population. Further research is also needed to determine the mechanism(s) for the increased liver disease progression and optimal treatment goals.

PDF

http://onlinelibrary.wiley.com/doi/10.1002/hep.22883/pdf

 

June 1, 2012 at 2:56 pm


Calendar

June 2012
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  

Posts by Month

Posts by Category